AstraZeneca’s (AZN) positive interim results for its COVID-19 vaccine Monday was met with some confusion as health experts and Wall Street attempted to parse the company’s “up to 90%” and “average 70%” vaccine efficacy claims. The vaccine candidate was tested in two different ways, resulting in two different efficacy rates — 62% and 90%— which the company averaged at 70%. The lower efficacy was from two full doses given a month apart, the higher efficacy came from the first… Source link
Read More »AstraZeneca could expand US trial to pursue 90% efficacious vaccine
